TRMT112 and central nervous system cancer: By analyzing CGGA dataset, the expression of TRMT112 which modifies m2G6 was significantly higher in the GBM group than that in the grade II glioma group (Fig. 3C), while the expression of TRMT10A which modifies m1G9 in the GBM group was significantly lower than that in the grade II glioma group (Fig. 3D).